/RVNC

RVNC Stock - Revance Therapeutics, Inc.

Q: What is the analyst price target for RVNC?

Analyst price target information is not currently available for RVNC.

Q: What is RVNC's market cap?

Market capitalization information is not currently available for RVNC.

Healthcare|Biotechnology|NASDAQ

$3.65+0.00%

+$0.00 (+0.00%) • Feb 6

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+484.4%upside

Target: $21.33

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for RVNC

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2019

FY2020

FY2021

FY2022

FY2023

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.95

52W High$7.56

52W Low$2.30

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2023	FY2022	FY2021	FY2020	FY2019
Revenue	$234.04M	$132.56M	$77.80M	$15.32M	$413,000
Gross Profit	$81.88M	$80.90M	$54.39M	$10.56M	$-102,448,000
Gross Margin	35.0%	61.0%	69.9%	68.9%	-24805.8%
Operating Income	$-316,777,000	$-272,169,000	$-274,676,000	$-273,162,000	$-164,459,000
Net Income	$-323,986,000	$-356,422,000	$-286,824,000	$-282,089,000	$-156,217,000
Net Margin	-138.4%	-268.9%	-368.7%	-1840.7%	-37824.9%
EPS	$-3.83	$-4.90	$-4.25	$-4.86	$-3.59

Company Overview

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing DaxibotulinumtoxinA in preclinical trial for the treatment of migraine, as well as a topical program for various indications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

20%

Hold / Neutral

80%

Sell / Underperform

Analyst Consensus🔴 Bearish

1 Bullish4 Neutral/Bearish

Price Targets

$19

Average Target

↑ 431.5% Upside

Now

Low

$19

Average

$33

High

Based on 5 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
January 29th 2024	Mizuho	Downgrade	Neutral	$9← $16
January 9th 2024	Goldman	Downgrade	Neutral	$8← $30
August 16th 2023	Exane BNP Paribas	Upgrade	Neutral	$20
October 11th 2022	Morgan Stanley	Initiation	Equal Weight	$27
September 22nd 2022	Goldman	Initiation	Buy	$33

Earnings History & Surprises

RVNC

Beat Rate

65%

Last 17 quarters

Avg Surprise

-7.3%

EPS vs Estimate

Beats / Misses

11/6

Last 12 quarters

Latest EPS

$-0.62

Q1 2025

EPS Surprise History

Q2 23

+1.3%

$-0.74vs$-0.75

Q3 23

-11.1%

$-0.80vs$-0.72

Q4 23

+27.5%

$-0.74vs$-1.02

Q1 24

+21.5%

$-0.62vs$-0.79

Q2 24

+18.2%

$-0.54vs$-0.66

Q3 24

+25.0%

$-0.36vs$-0.48

Q4 24

-5.7%

$-0.37vs$-0.35

Q1 25

-113.8%

$-0.62vs$-0.29

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q4 2025	Nov 5, 2025	—	—	—	—
Q3 2025	Aug 6, 2025	—	—	—	—
Q2 2025	May 7, 2025	—	—	—	—
Q1 2025	Feb 26, 2025	$-0.29	$-0.62	-113.8%	✗ MISS
Q4 2024	Nov 7, 2024	$-0.35	$-0.37	-5.7%	✗ MISS
Q3 2024	Aug 8, 2024	$-0.48	$-0.36	+25.0%	✓ BEAT
Q2 2024	May 9, 2024	$-0.66	$-0.54	+18.2%	✓ BEAT
Q1 2024	Feb 28, 2024	$-0.79	$-0.62	+21.5%	✓ BEAT
Q4 2023	Nov 8, 2023	$-1.02	$-0.74	+27.5%	✓ BEAT
Q3 2023	Aug 8, 2023	$-0.72	$-0.80	-11.1%	✗ MISS
Q2 2023	May 9, 2023	$-0.75	$-0.74	+1.3%	✓ BEAT
Q1 2023	Feb 28, 2023	$-1.04	$-1.82	-75.0%	✗ MISS
Q4 2022	Nov 8, 2022	$-0.85	$-1.17	-37.6%	✗ MISS
Q3 2022	Aug 9, 2022	$-0.91	$-0.88	+3.3%	✓ BEAT
Q2 2022	May 10, 2022	$-0.91	$-0.94	-3.3%	✗ MISS
Q1 2022	Feb 28, 2022	$-0.98	$-0.93	+5.1%	✓ BEAT
Q4 2021	Nov 9, 2021	$-1.15	$-1.10	+4.3%	✓ BEAT
Q3 2021	Aug 5, 2021	$-1.14	$-1.07	+6.1%	✓ BEAT
Q2 2021	May 10, 2021	$-1.19	$-1.08	+9.2%	✓ BEAT
Q1 2021	Feb 22, 2021	$-1.25	$-1.24	+0.8%	✓ BEAT

Frequently Asked Questions about RVNC

What is RVNC's current stock price?

Revance Therapeutics, Inc. (RVNC) is currently trading at $3.65 per share. The stock has moved +0.00% today.

What is the analyst price target for RVNC?

The average analyst price target for RVNC is $21.33, based on 1 analyst.

What sector is Revance Therapeutics, Inc. in?

Revance Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is RVNC's market cap?

Revance Therapeutics, Inc. has a market capitalization of $0.38 billion, making it a small-cap company.

Does RVNC pay dividends?

No, Revance Therapeutics, Inc. does not currently pay a dividend to shareholders.